Ji, Y., et al. Exploring the Impact of Adjuvants on Vaccine Immunity Through Hematopoietic Cells. Vaccines (Basel), 2026 Feb 5, 14(2):155. PMID: 41746076

The paper explores how various adjuvants influence the immune response and hematopoietic pathways, particularly focusing on megakaryocytes and platelets, which are emerging as key players in vaccine-induced immunity. By analyzing multiple adjuvant formulations in a non-human primate model, the study provides crucial insights into the molecular and cellular mechanisms that underpin the strength and durability of vaccine responses. Understanding these pathways is essential for designing more effective vaccines with sustained protection, especially as adjuvants are central to enhancing immune responses beyond what traditional formulations like alum can achieve. 

The key results and findings of the study are as follows: 

• • Enhanced Antibody Responses: Several adjuvant formulations, particularly those containing MPL and QS21 (Group 6), elicited significantly higher and more durable HPV16-specific antibody titers compared to alum alone. Notably, Group 6 showed a 14.42-fold increase in antibody levels at week 54, indicating strong and prolonged immune responses.
  • Adjuvant Impact on Gene Expression: Early transcriptional profiling revealed that formulations associated with higher antibody responses also showed stronger enrichment in pathogen-influenced signaling pathways, cellular and humoral immune pathways, and megakaryocyte/platelet development pathways. These gene expression signatures suggest that adjuvants modulate innate and adaptive immunity at the molecular level.
  • Role of Hematopoietic Cells: The study provided evidence that adjuvants influence hematopoietic pathways, particularly involving megakaryocytes and platelets, which are involved in immune modulation and inflammation. Distinct transcriptional signatures related to megakaryocyte and platelet biology correlated with higher vaccine responses.
  • Early Immune Signatures as Predictors: The results suggest that early activation of innate immune and megakaryocyte/platelet pathways may serve as systems-level biomarkers for predicting the magnitude and durability of vaccine-induced antibody responses.
  • Formulation-Dependent Modulation: The study demonstrates that the choice of adjuvant components and delivery platforms significantly affects both immunogenicity and underlying molecular pathways, indicating the importance of rational adjuvant design for optimal vaccine performance. 

    Overall, these findings underscore the complexity of adjuvant effects, highlight the importance of hematopoietic pathways in vaccine responses, and suggest pathways and biomarkers that could guide future adjuvant development for next-generation vaccines with improved longevity and efficacy.